News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing: 1–36
Matches: 80
Sources here: 19
Companies here: 2

Search results Stored financial headlines Latest headline 09:10, 15 August 2026

Active search

80 matching headlines

Ticker or company: NVSMain company stories

Clear

Latest09:10 · 15 August 2026

MarketBeat Analyst action

D.A. Davidson & CO. Lowers Position in Novartis AG $NVS

D.A. Davidson & CO. reduced its stake in Novartis AG (NYSE:NVS) by 23.4% in the second quarter, selling 49,798 shares and holding 163,017 shares valued at $25.55 million. Despite this, several other institutional investors, including Auto Owners Insurance Co. and Morgan Stanley, significantly increased their positions in Novartis. The article also provides an overview of Novartis's financial performance, …

Main company 🇺🇸 United States

Read at MarketBeat

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

Just inNext headlines

11:18 14 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Mirae Asset Global Investments Co. Ltd. Purchases 56,424 Shares of Novartis AG $NVS

Mirae Asset Global Investments Co. Ltd. significantly increased its stake in Novartis AG (NVS) by 40.4% in the second quarter, acquiring an additional 56,424 shares, bringing its total holdings to 195,986 shares valued at approximately $30.7 million. Other institutional investors also expanded their positions, …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:33 13 Aug 2026

finance.yahoo.com Analyst action Main company 🇺🇸 United States

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

15:30 13 Aug 2026

marketscreener.com Market update Main company 🇺🇸 United States

Novartis Wins UK Court Challenge to Entresto Patent

Novartis has successfully defended its patent for the blockbuster heart drug Entresto in a UK court challenge. The article, published by MT Newswires, indicates this as a significant win for the pharmaceutical giant. Further details require a membership to the financial news platform.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:56 13 Aug 2026

Reuters Market update Main company 🇺🇸 United States

Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent

Novartis has successfully defended its patent for the heart drug Entresto in a UK court against Accord Healthcare, a subsidiary of Intas Pharmaceuticals, which intended to launch a generic version. The High Court rejected Accord's claim that Novartis's patent was invalid, affirming the patent's …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

11:42 13 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Novartis AG $NVS Shares Purchased by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in Novartis AG (NYSE:NVS) during the second quarter, purchasing an additional 9,086 shares to bring its total holdings to 19,690 shares valued at approximately $3.09 million. Other institutional investors also expanded their positions, though hedge funds …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

11:42 13 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

SOA Wealth Advisors LLC. Buys 14,416 Shares of Novartis AG $NVS

SOA Wealth Advisors LLC. significantly increased its stake in Novartis AG (NYSE:NVS) by 4,316.2% in the second quarter, acquiring 14,416 additional shares to reach a total of 14,750 shares valued at $2.31 million. Other institutional investors also adjusted their positions in Novartis, with institutions …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:41 11 Aug 2026

BigGo Finance Market update Main company 🇺🇸 United States

Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis

A debate in Boston featured RA Capital founder Peter Kolchinsky and Ginkgo Bioworks CEO Jason Kelly discussing whether the U.S. should ban in-licensing of drug assets from China. Kelly argued the U.S. has significant leverage due to its pharmaceutical revenue share, while Kolchinsky warned …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

03:11 10 Aug 2026

ET Pharma Deals and strategy Main company 🇺🇸 United States

Dr Reddy’s to discontinue marketing of Novartis in-licensed brands from October

Dr. Reddy's Laboratories will cease marketing select Novartis India brands from October 1, 2026, due to a change in Novartis India's ownership. This decision follows Novartis AG's divestment of its controlling stake in Novartis India to private equity firm ChrysCapital. Dr. Reddy's had an …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

20:10 6 Aug 2026

TipRanks Earnings Main company 🇺🇸 United States

Novartis Ag (0K9E) Q2 2026 Earnings Report - Results, Call & Slides

Novartis Ag reported strong Q2 2026 earnings, beating analyst expectations with an EPS of $2.41 and revenue of $14.42 billion. The company reaffirmed its full-year guidance, driven by robust performance from priority brands like KISQALI, LEQVIO, and Scemblix, and significant progress in its pipeline …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:40 6 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS

The Manufacturers Life Insurance Company reduced its stake in Novartis AG by 39.4% in the first quarter, selling 24,216 shares and retaining 37,202 shares valued at $5.68 million. Despite this, other major institutions like Morgan Stanley and Fisher Asset Management increased their holdings, with …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

19:11 5 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS

Segall Bryant & Hamill LLC acquired a new stake of 18,792 shares in Novartis AG (NVS) during the first quarter, valued at approximately $2.93 million. This purchase contributes to the 13.12% ownership of Novartis stock by institutional investors and hedge funds. Novartis recently reported …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

07:39 5 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS

Glenmede Trust Co. NA increased its stake in Novartis AG (NVS) by 16% in the first quarter, purchasing 8,680 shares to bring its total holdings to 63,066 shares valued at $9.6 million. Other institutional investors also adjusted their positions in Novartis, which has a …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

08:09 4 Aug 2026

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Novartis AG (NVS) Investor Outlook: Analyzing Market Position Amidst a Strong Dividend Yield and Analyst Ratings

Novartis AG (NVS) is a global pharmaceutical leader with a market cap of $296.8 billion, known for its stable market position and innovative pipeline. The company offers an attractive 3.04% dividend yield with a 71.60% payout ratio, making it appealing to income-focused investors. While …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

22:00 3 Aug 2026

Simply Wall St. Regulatory and legal Main company 🇺🇸 United States

Novartis (SWX:NOVN) Wins FDA Approval For Pluvicto In Earlier Prostate Cancer

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novartis received FDA approval for Pluvicto in PSMA positive metastatic hormone sensitive prostate cancer. The decision expands Pluvicto's label to cover all stages …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

18:11 3 Aug 2026

Benzinga Earnings Main company 🇺🇸 United States

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto

The FDA has approved Novartis' Pluvicto for an earlier stage of metastatic hormone-sensitive prostate cancer, significantly expanding the eligible patient population. This approval is based on the Phase 3 PSMAddition study, which showed a substantial reduction in disease progression or death when Pluvicto was …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:34 3 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

The second-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector is pretty good so far. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the pharma/biotech sector kicked off last month when pharma bellwether …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:11 1 Aug 2026

Novartis Market update Main company 🇺🇸 United States

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Novartis announced that the FDA has approved Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), expanding its use across all stages of PSMA-positive metastatic prostate cancer. This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, combined with standard of …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:12 1 Aug 2026

nasdaq.com Regulatory and legal Main company 🇦🇷 Argentina

FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer

(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer, also known as …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +40.1% · Next-week setup positive 58.8%

03:40 1 Aug 2026

TradingView Earnings Main company 🇺🇸 United States

Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSC

Novartis AG (BCBA:NVSC) generated a total revenue of $54.53 billion USD last year. The Oncology segment was its top-performing segment, contributing $17.63 billion USD, an increase from the previous year. The United States was the largest geographical contributor, accounting for $24.44 billion USD of …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

01:39 1 Aug 2026

TipRanks Earnings Main company 🇺🇸 United States

Novartis Ag (0K9E) Q1 2025 Earnings Report - Results, Call & Slides

Novartis Ag (0K9E) released its Q1 2025 earnings report, surpassing analyst expectations with an actual EPS of $2.28 against a consensus of $2.11, and actual revenue of $13.24 billion exceeding the expected $13.08 billion. This represents a significant year-over-year revenue growth of 12.60% and …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

19:42 30 Jul 2026

OpenSecrets Market update Main company 🇺🇸 United States

Novartis AG Lobbyists, 2023

This article from OpenSecrets.org details the lobbying activities of Novartis AG in 2023. It lists 73 lobbyists hired by Novartis, with 56 (76.7%) of them having previous federal government experience, indicating a significant "revolving door" phenomenon. The report also names the firms that employed …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:09 30 Jul 2026

BioSpectrum India Deals and strategy Main company 🇺🇸 United States

ChrysCapital acquires 70.68% stake in Novartis India

Private equity firm ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited (NIL), a BSE-listed company previously held by Novartis AG. This acquisition marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector, aiming to transform Novartis India into a leading branded-generics …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

18:20 29 Jul 2026

nasdaq.com Earnings Main company 🇦🇷 Argentina

3 Dividend Stocks to Buy for a Lifetime of Passive Income

Key Points Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device market. Visa's large ecosystem can enable it to tap into lucrative growth opportunities and fend …

NVS main company NVS main company

Sharemaestro market context Trend signal active 52 weeks +40.1% · Next-week setup positive 58.8%

22:40 27 Jul 2026

OpenSecrets Market update Main company 🇺🇸 United States

Novartis AG Lobbyists, 2017

This article from OpenSecrets details the lobbyists employed by Novartis AG in 2017, highlighting that out of 84 named lobbyists, 66 (78.6%) had previous federal government experience, including one former member of Congress. It lists the lobbying firms and individual lobbyists working for Novartis, …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:36 27 Jul 2026

finance.yahoo.com Earnings Main company 🇦🇷 Argentina

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

The second-quarter 2026 reporting cycle for the Medical sector is picking up pace. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the Medical sector kicked off earlier this month when pharma bellwether Johnson & Johnson posted encouraging earnings results. …

NVS main company NVS main company

Sharemaestro market context Trend signal active 52 weeks +40.1% · Next-week setup positive 58.8%

14:40 27 Jul 2026

OpenSecrets Market update Main company 🇺🇸 United States

Novartis AG Lobbyists, 2022

This article from OpenSecrets details the lobbyists working for Novartis AG in 2022, including information on their hiring firms and whether they are part of the "revolving door" of former government employees. It lists 60 named lobbyists, with 47 (78.3%) having previous federal government …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:40 27 Jul 2026

Moomoo Analyst action Main company 🇺🇸 United States

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180

TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and maintained its price target of $180. This indicates an analyst's view that the stock is expected to perform in line with the market, with the current valuation justifying the existing price.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

13:47 27 Jul 2026

Market source Earnings Main company 🇦🇷 Argentina

Novartis AG (NVS) Stock Forecasts

Argus Research has raised its target price for Novartis AG (NVS) to $170. The pharmaceutical company, based in Switzerland, focuses on immunology, neuroscience, oncology, and cardiovascular, renal, and metabolic therapies. Argus analyst Jasper Hellweg covers Growth Pharmaceutical, Medical Technology, and Financial Technology companies for …

NVS main company NVS main company

Sharemaestro market context Trend signal active 52 weeks +40.1% · Next-week setup positive 58.8%

06:12 27 Jul 2026

TradingView Deals and strategy Main company 🇺🇸 United States

Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop

Novartis reported Q2 net sales up 1-3% and beat EPS estimates, but experienced a 50% drop in Entresto sales due to U.S. generics. Despite this, the company reiterated its full-year guidance and is investing heavily in acquisitions and manufacturing expansion, with key trial readouts …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:40 25 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Novartis AG Revenue Breakdown – BX:NOT

Novartis AG's latest financial data shows a total revenue of 43.23 billion CHF. The Oncology segment was the top performer, contributing 13.98 billion CHF, an increase from 12.98 billion CHF in the previous year. The United States was the largest regional contributor, accounting for …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

13:42 25 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSB

Novartis AG (BCBA:NVSB) generated significant revenue last year, reaching 79.15 trillion ARS. The Oncology segment was the top performer, contributing 25.59 trillion ARS, and the United States was the largest regional contributor with 35.47 trillion ARS.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

23:12 24 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA

Novartis AG Sponsored ADR (SWB:NOTA) generated €46.43 billion in revenue last year. Its top-performing segment was Oncology, contributing €14.33 billion. The company's largest regional contribution came from the United States, accounting for €19.86 billion.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

05:11 24 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Revenue Beat: Novartis AG Beat Analyst Estimates By 5.7%

Novartis AG announced interim results showing revenues of US$28 billion, a 5.7% beat on analyst predictions, with statutory earnings per share at US$1.71, in line with forecasts. Despite the revenue beat, analysts haven't significantly altered their 2026 forecasts, maintaining revenue estimates at US$57.5 billion …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

10:40 23 Jul 2026

www.marketscreener.com Analyst action Main company 🇺🇸 United States

NOVARTIS AG : Jefferies gives a Neutral rating

Jefferies analyst Michael Leuchten has maintained a Neutral rating on Novartis AG (NOVN) stock, keeping the target price unchanged at CHF 110. This announcement comes amidst other recent analyst ratings for Novartis, including Neutral ratings from DZ Bank and Bernstein, and Buy ratings from …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:31 22 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇷 Argentina

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

The CAR T-cell therapy for NHL market is witnessing rapid expansion, driven by the transition from conventional chemo-immunotherapy to advanced cell-based treatment modalities. Strong efficacy in R/R disease, growing adoption in 2L and beyond, and the launch of emerging therapies such as Zamtocabtagene autoleucel …

NVS main company NVS main company

Sharemaestro market context Trend signal active 52 weeks +40.1% · Next-week setup positive 58.8%